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ABSTRACT
Objectives We studied time trends in seasonal influenza 
vaccination and associations with socioeconomic and 
health- related determinants in Switzerland, overall and in 
people aged ≥65 years.
Design Three cross- sectional surveys.
Participants Individuals who participated in the Swiss 
Health Surveys 2007, 2012 and 2017. We calculated the 
proportion reporting influenza vaccination in the last 12 
months, and performed multivariable logistic regression 
analyses.
Results We included 51 582 individuals in this analysis. 
The median age was 49 years (IQR 25–64), and 27 518 
were women (53.3%). The proportion of reporting a history 
of influenza vaccination overall was 31.9% (95% CI 31.4 
to 32.4); and dropped from 34.5% in 2007 to 28.8% in 
2017. The uptake of vaccination within the past 12 months 
was 16% in 2007 and similar in 2012 and 2017 (around 
14%). In people with chronic disease, uptake dropped from 
43.8% in 2007 to 37.1% in 2012 and to 31.6% in 2017 
(p<0.001). In people aged ≥65 years, uptake dropped 
from 47.8% in 2007 to 38.5% in 2012 to 36.2% in 2017 
(p<0.001). In logistic regression, self- reported vaccination 
coverage decreased in the 65–75 years old (adjusted 
OR (aOR) 0.56, 95% CI 0.48 to 0.66 between 2007 and 
2012; aOR 0.89, 95% CI 0.77 to 1.03 between 2012 and 
2017). Uptake was positively associated with the ≥65 age 
group, living in French- speaking and urban areas, history 
of smoking, bad self- reported health status, private/
semiprivate health insurance, having a medical profession 
and having any underlying chronic disease.
Conclusion Influenza vaccination coverage was low in 
older and chronically ill persons. Significant efforts are 
required in preparing for the influenza season 2020/2021 
to reduce the double burden of COVID-19 and seasonal 
influenza. These efforts should include campaigns but also 
novel approaches using social media.
INTRODUCTION
Seasonal influenza is pandemic, and a chal-
lenge for surveillance, control and treatment.1 
Worldwide, it causes 3–5 million cases of severe 
illness each year and kills 250 000–500 000 
people,2 particularly infants, the elderly and 
the chronically ill. In Switzerland, influenza 
is responsible for 111 000–331 000 medical 
consultations yearly and 1000–5000 hospital-
isations.3 The current COVID-19 pandemic 
shows the impact of respiratory viruses on the 
burden of infectious diseases and the impor-
tance of vaccines in the control of viral respi-
ratory diseases.4 5
In 2003, the World Health Assembly 
adopted a resolution urging member states 
to reach a target for uptake of influenza 
vaccines of 75% among people at high risk by 
2010.6 The Federal Office of Public Health in 
Switzerland has vaccine recommendations in 
place since 2007, which target mainly elderly 
people, but also those with chronic illnesses 
(including children older than 6 months), 
premature infants, pregnant women, resi-
dents of long- term healthcare facilities and 
those are in regular contact with vulnerable 
populations.7
We earlier analysed the data from the Swiss 
Health Survey 2007 and 2012 and showed 
that overall influenza vaccine uptake in 
Strengths and limitations of this study
 ► The Swiss Health Survey is a nationwide, represen-
tative survey that is repeated every 5 years using the 
same sampling methodology.
 ► Data analysis of the Swiss Health Survey 2007, 
2012 and 2017 focussing on influenza vaccine 
uptake overall and in the age group ≥65 years in 
Switzerland.
 ► We calculated per cent of people reporting having 
been vaccinated, analysed time trends and associ-
ations between vaccination status and sociodemo-
graphic and health- related factors.
 ► The analyses were weighted and adjusted for a 
range of potential confounders, which did not sub-
stantially change the results.
 ► Influenza vaccination status is self- reported in the 















pen: first published as 10.1136/bm





2 Zürcher K, et al. BMJ Open 2021;11:e041354. doi:10.1136/bmjopen-2020-041354
Open access 
Switzerland decreased from 2007 to 2012.8 To examine 
recent trends and associations of sociodemographic char-
acteristics and health- related factors with influenza vacci-
nation practices in Switzerland, we analysed the data from 
the most recent nationally representative health survey, 




The cross- sectional Swiss Health Survey has been 
conducted every 5 years since 1992 by the Swiss Federal 
Statistical Office (SFSO). The survey is a multistage prob-
ability sample drawn from all residents not living in insti-
tutions in Switzerland.8 9 Conducted between January 
and December of the year, the survey collects data 
using computer- assisted telephone interviews and self- 
completed questionnaires.
We compared the data set from 2017 with the data from 
2012 and 2007 and only used survey data from the written 
forms. We excluded the telephone interviews because 
they were shorter and did not include all the questions. 
We included a total of 51 582 people who responded to a 
written questionnaire; 14 393 responded in 2007, 18 357 
in 2012 and 18 632 in 2017.
Data collection and definitions
From all three surveys, we extracted data on influenza 
vaccination within the past 12 months.9
The questionnaire collected demographic and socio-
economic as well as health- related information (table 1) 
on chronic diseases such as diabetes, cancer, lung, cere-
brovascular and cardiovascular disease. The basic health 
insurance is mandatory in Switzerland and provides cover 
for illness, maternity, and accidents, offering the same 
range of services to all insured people.10 The respon-
dents’ health insurance plan regarding coverage in case 
of hospitalisation (private, semiprivate, or general ward), 
free choice of physicians and coverage of complementary 
medicine (including acupuncture, traditional Chinese 
medicine, homoeopathy, and osteopathy) in the past 12 
months was recorded as well.
Pregnancy was recorded as current pregnancy among 
women 15–49 years old. Current chronic lung diseases 
included asthma, chronic bronchitis and emphysema. 
Diabetes was defined by the use of any diabetic drug, 
cardiovascular disease by the use of any heart medica-
tion, and all other chronic diseases were recorded as self- 
reported. We defined any chronic disease as the presence 
of at least one of the mentioned diseases. Healthcare 
workers were defined as individuals reporting profession 
in the healthcare system.
Cantons are the administrative subdivisions of Switzer-
land (see figure 1).
Statistical analysis
For each of the three survey years we calculated the 
proportions (overall and ≥65 years) that reported having 
been vaccinated within the last 12 months. We estimated 
associations between vaccination status and sociodemo-
graphic and health- related factors. We included an inter-
action term with the year of survey and the variable of 
interest in multivariable logistic regression models. We 
used the SFSO’s survey weights and reported all propor-
tions and unadjusted and adjusted OR (aOR) with the 
corresponding 95% CIs derived from robust SE calcu-
lations (table 2). All analyses were performed in Stata 
(V.15.1).
We visualised changes in the frequency of vaccination 
uptake, and geographical distributions of the population 
that reported vaccination for influenza at the cantonal 
level using ArcGIS V.10.5 (Redlands, California, USA).
RESULTS
Trends of influenza vaccinations over time
The proportion of survey participants reporting a history 
of influenza vaccination overall was 31.9% (95% CI 31.4 
to 32.4), having dropped from 34.5% in 2007 to 28.8% 
in 2017. The proportion reporting vaccination within the 
past 12 months was 16.4% (95% CI 15.6 to 17.2) in 2007, 
dropped to 14.1% (95% CI 13.5 to 14.8) in 2012, and 
remained at this level in 2017 (14.4%, 95% CI 13.8 to 15.0, 
p<0.001, table 1). Among those ≥65 years old, the prin-
cipal target population of the Swiss recommendations,7 
vaccination in the past 12 months dropped from 47.8% 
(95% CI 45.7 to 49.9) in 2007 to 38.5% (95% CI 36.6 to 
40.5) in 2012, and 36.2% (95% CI 34.6 to 37.9) in 2017 
(p<0.001). For those with any chronic disease, another 
at- risk population, the frequency of influenza vaccination 
dropped from 43.8% (95% CI 40.9 to 46.8) in 2007 to 
37.1% (95% CI 34.6 to 39.7) in 2012, and further to 31.6% 
(95% CI 29.7 to 33.6) in 2017. Similarly, a decrease in 
vaccine uptake was seen in people with poor self- reported 
health status (39.4%, 33.1% and 27.0%, figure 2).
From 2007 to 2012 the self- reported influenza vaccina-
tion in the last 12 months decreased in age group 15–19 
years (aOR 0.51, 95% CI 0.27 to 0.99) but increased 
from 2012 to 2017 in the younger age groups (eg, aOR 
1.59, 95% CI 0.92 to 2.74 in the 15–19 years age group; 
aOR 1.19. 96% CI 0.84 to 1.69 in the 20–29 years age 
group, figure 2 and table 2). In contrast, it decreased in 
the 65–75 years old between 2007 and 2017 (aOR 0.56, 
95% CI 0.48 to 0.66 for 2007–2012; aOR 0.89, 95% CI 
0.77 to 1.03 for 2012–2017, table 2). The p value from the 
test for an interaction between period and age group was 
0.01 for 2007–2012 and 0.051 for 2012–2017. In pregnant 
women, an increase of influenza vaccination was observed 
between 2007 and 2012 (aOR 4.43, 95% CI 0.96 to 20.42, 
p=0.02), with no further increase between 2012 and 2017 
(aOR 0.94, 95% CI 0.36 to 2.47, p=0.45). The temporal 
trends over the period 2007–2012 and 2012–2017 were 
not associated with age, language region, urban/rural 
setting, citizenship, any chronic disease, smoking status, 
use of complementary medicine or type of hospital stay 
insurance (p>0.05, table 2).
by copyright.
 on F











pen: first published as 10.1136/bm































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm





5Zürcher K, et al. BMJ Open 2021;11:e041354. doi:10.1136/bmjopen-2020-041354
Open access
Figure 1 Geographical distribution (by canton) of people reporting influenza vaccination in the last 12 months in Switzerland, 
2007 to 2017. (A) Overall; (B) people aged ≥65 years. na, not applicable (no. of respondents <100).
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Influenza vaccination status in different population groups
In all three surveys, self- reported influenza vaccination in 
the last 12 months was highest in the age group ≥65 years, 
and also higher in urban settings, among Swiss citizens, 
former smokers and in persons with supplemental health 
insurance (table 1). In all three surveys, the proportion 
of self- reported influenza vaccination was higher in the 
French- speaking and Italian- speaking region compared 
with the German region. Persons with chronic diseases 
were more frequently vaccinated for influenza, with 
uptake ranging from around 20% to 57% depending on 
age group and type of chronic disease. A lower propor-
tion of self- reported vaccination was observed in ages 15 
years to 50 years (range 4%–9%), current smokers, and 
person who reported their health status as very good. The 
regional differences in the vaccination status in the last 12 
months in the overall population and the ≥65 age group 
are shown in figure 1A, B.
Individual and health system factors associated with the 
influenza vaccination status
In all three surveys, influenza vaccination in the last 
12 months was positively associated with age 65 years or 
older, living in French- speaking and urban areas, having 
a tertiary education, history of smoking, bad self- reported 
health status, private/semiprivate hospital stay insurance, 
being a healthcare worker and having any underlying 
chronic disease. Use of any complementary medicine 
therapy was negatively associated with influenza vaccina-
tion (aOR 0.72, 95% CI 0.67 to 0.80). We found no asso-
ciation with sex, body mass index or non- Swiss citizenship 
(table 3). Similar findings were observed when analysing 
only participants’ ≥65 years old. Online supplemental 
table 1 shows unadjusted and aORs of the associations 
between self- reported vaccination for influenza in the 
last 12 months and sociodemographic characteristics and 
health- related factors.
DISCUSSION
Progress toward the WHO target of 75% vaccination 
coverage among high- risk groups has not only stalled 
in Switzerland, some of the gains made in earlier years 
were lost by 2017. Of particular concern is that the self- 
reported seasonal influenza vaccination rate among 
elderly persons declined from 47.8% in 2007 to 38.5% in 
2012, and declined further to 36.2% in 2017. People at 
risk due to underlying chronic diseases reported coverage 
of influenza vaccination of 31.6% in 2017. Overall, after 
declining from 16.4% in 2007 to 14.1% in 2012, coverage 
in Switzerland was, with 14.4%, similar in 2017.
A decline in influenza vaccine coverage in recent years 
has been observed in other European countries. In the 
European Region of WHO, vaccine uptake in older 
people ranged from 0.03% to 76.3% over seven seasons 
(2008/2009–2014/2015). The median was 34.4%. In 
2014/2015, only Scotland reached the WHO and Euro-
pean Council goal with an uptake of 75%. Among coun-
tries providing data for seasons 2008/2009 and 2014/2015, 
over half reported a drop in vaccination coverage among 
older people.11 Among people with chronic diseases, 
coverage in the European Region ranged from 0.3% in 
Kyrgyzstan to 86.8% in Georgia in 2014/2015.11
From a historical perspective, vaccines have substan-
tially reduced the burden for infectious disease (eg, polio, 
measles, mumps and rubella) or have been eradicated 
(small pox).12 Vaccine safety have always been a concern. 
For example, measles vaccine was falsely linked to autism 
in the 1990s, which led to a dramatically drop in vaccine 
coverage in the UK and other countries. Misleading 
Figure 2 Temporal trends of selected groups of people reporting influenza vaccination in the last 12 months in Switzerland, 
comparing 2007 to 2017. Percent of people reporting having been vaccinated and the 95% CIs are presented. Good health: 
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Table 3 Associations of having been vaccinated for influenza in the last 12 months with sociodemographic characteristics and 
health- related factors (as compared with no vaccination) in Switzerland, 2007 to 2017, overall and among people ≥65 years old
Characteristic
All ≥65 years old
Adjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Year of survey <0.001 <0.001
  2007 1 1
  2012 0.74 (0.66 to 0.83) 0.60 (0.51 to 0.71)
  2017 0.72 (0.64 to 0.80) 0.57 (0.49 to 0.66)
Age group, years <0.001 <0.001
  15–19 1.07 (0.67 to 1.71) –
  20–29 1 –
  30–39 1.05 (0.77 to 1.44) –
  40–49 1.32 (0.99 to 1.75) –
  50–64 2.27 (1.74 to 2.96) –
  65–75 6.26 (4.78 to 8.20) 1
  >75 12.94 (9.81.17.08) 2.04 (1.82 to 2.30) <0.001
Sex 0.66 0.37
  Male 1 1
  Female 0.97 (0.88 to 1.08) 1.06 (0.93 to 1.21)
Pregnancy 0.67 –
  Yes 0.91 (0.56 to 1.70) –
  No 1 –
BMI group 0.87 0.93
  Underweight 1 1
  Normal 0.97 (0.74 to 1.28) 0.88 (0.58 to 1.34)
  Overweight 0.94 (0.72 to 1.25) 0.89 (0.59 to 1.36)
  Obese 0.99 (0.74 to 1.32) 0.91 (0.58 to 1.41)
Language region <0.001 0.01
  German- speaking 1 1
  French- speaking 1.31(1.20 to 1.44) 1.22 (1.07 to 1.38)
  Italian- speaking 0.95 (0.82 to 1.12) 1.05 (0.86 to 1.29)
Setting <0.001 0.02
  Urban 1.24 (1.12–1.38) 1.19 (1.03–1.37)
  Rural 1 1
Citizenship 0.80 0.20
  Swiss 1 1
  Non- Swiss 0.98 (0.85 to 1.13) 0.87 (0.70 to 1.08)
Education level <0.001 0.06
  Primary 1 1
  Apprenticeship 1.00 (0.88 to 1.14) 1.05 (0.89 to 1.23)
  Secondary 1.11 (0.93 to 1.31) 1.14 (0.91 to 1.43)
  Tertiary 1.26 (1.09 to 1.46) 1.26 (1.04 to 1.53)
Smoking <0.001 0.009
  Never smoked 1 1
  Former smoker 1.17 (1.05 to 1.28) 1.22 (1.07 to 1.39)
  Current smoker 0.91 (0.81 to 1.02) 1.01 (0.85 to 1.20)
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information about the safety of vaccines might have 
increased the vaccine hesitancy and reduced the coverage 
of some vaccines.13
The decline in coverage and an increase in vaccine 
hesitancy is of general concern. In the last years, several 
countries of the WHO European Region including Swit-
zerland, had large outbreaks of vaccine- preventable 
diseases, including measles, rubella and influenza. Swit-
zerland and other countries identified steps to improve 
vaccination coverage for vaccine- preventable infec-
tious diseases.14 15 The relationship between vaccination 
uptake, knowledge, attitudes and awareness is complex.16 
Reasons for people not getting vaccinated against influ-
enza include underestimation of disease severity, fear of 
side effects and the cost of vaccines.17–19 Often people are 
unaware that they should receive the vaccination.17 For 
the seasonal influenza, the varying efficiency ranging from 
30% to 60% depending on the season could play a role in 
the reduced coverage over time.20 21 However, mathemat-
ical models of influenza and vaccination showed that the 
health burden associated with influenza is more sensitive 
to changes in vaccination coverage than to changes in 
vaccine efficacy.21 Of note, the coverage of measles vacci-
nation increased to almost 90% in young adults in Swit-
zerland, probably due to the campaigns and a national 
measles strategy.22 The experience with measles could 
serve as a model for public health actions influenza.
The advent of the novel COVID-19 SARS- CoV-2 has 
profoundly changed everyday life in Switzerland and 
elsewhere. It is unclear how the COVID-19 pandemic will 
affect attitudes toward vaccines. The director of the US 
Centers for Disease Control has warned that a possible 
second wave of COVID-19 could be worse than the first.23 
This has already been seen in the ‘Spanish influenza’ 
pandemic of 1918/1919. The Spanish influenza affected 
Switzerland in two waves. The first one occurred in July 
Characteristic
All ≥65 years old
Adjusted OR (95% CI) P value Adjusted OR (95% CI) P value
  Very good 1 1
  Good 1.16 (1.03 to 1.31) 1.30 (1.10 to 1.53)
  Moderate 1.56 (1.36 to 1.80) 1.65 (1.36 to 2.01)
  Bad 2.13 (1.70 to 2.65) 2.03 (1.46 to 2.81)
  Very bad 2.07 (1.26 to 3.40) 1.79 (0.92 to 3.45)
Hospital stay insurance <0.001 <0.001
  Basic 1 1
  Semiprivate 1.43 (1.30 to 1.59) 1.42 (1.24 to 1.63)
  Private 1.78 (1.56 to 2.03) 1.86 (1.56 to 2.21)
  Other 1.28 (0.86 to 1.92) 0.89 (0.50 to 1.58)
Use of any complementary medicine therapy* <0.001 <0.001
  Yes 0.72 (0.66 to 0.80) 0.65 (0.57 to 0.75)
  No 1 1
Chronic diseases†
  Any chronic disease 1.84 (1.69 to 2.09) <0.001 1.68 (1.51 to 1.88) <0.001
  Diabetes 1.54 (1.33 to 1.77) <0.001 1.46 (1.23 to 1.73) <0.001
  Lung disease 1.81 (1.46 to 2.26) <0.001 1.59 (1.16 to 2.18) 0.004
  Cerebrovascular disease 1.12 (0.74 to 1.69) 0.59 0.91 (0.58 to 1.42) 0.68
  Cardiovascular disease 1.50 (1.34 to 1.68) <0.001 1.44 (1.26 to 1.64) <0.001
  Cancer 1.22 (0.97 to 1.55) 0.09 1.05 (0.80 to 1.38) 0.12
  Healthcare worker’‡ 1.92 (1.64 to 2.24) <0.001 – –
Model adjusted for all variables included in the table. Unadjusted ORs are shown in online supplemental table 2.
*Current pregnancy in women 15–49 years.
†Use of any alternative therapy in the past 12 months (including acupuncture, traditional Chinese medicine, homeopathy, and osteopathy).
‡Any current chronic disease versus no chronic disease (reference); lung diseases: asthma bronchiale, chronic bronchitis and emphysema 
versus no lung disease (reference); diabetes: use of any diabetic drug versus no diabetes (reference); cardiovascular disease: use of any heart 
medication versus no cardiovascular disease (reference); all other diseases: self- reported disease versus no disease (reference).
§Estimates from separate models which included the variable ‘any chronic disease’ instead of specific chronic diseases.
¶Any profession in the healthcare system (in the 2007 survey, the veterinary professions were also included in this category) versus any other 
profession (reference).
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1918, the second, more severe one, in October–November 
1918.24 However, even in the absence of a second wave, a 
resurgence of COVID-19 that coincides with the start of 
the influenza season could significantly stress healthcare 
systems. An effective and safe vaccine against COVID-19 
is unlikely to become widely available in 2020. Therefore, 
low influenza vaccination rates at around half the 75% 
coverage recommended for high- risk groups constitute a 
hazard that merits prompt, focused attention by public 
health authorities.
A concerted effort to increase influenza vaccination 
coverage in 2020/2021, when the COVID-19 pandemic to 
continue to pose a threat to the public’s health, is urgently 
needed. Influenza vaccination prevents deaths, morbidity, 
hospital admissions and other adverse health outcomes, 
in target populations such as older people, chronically ill 
people,25–30 and also children31 and pregnant women.32 
The continued promotion of infection control measures 
such as avoiding close contact with sick people, covering 
one’s nose and mouth while coughing or sneezing, social 
distancing and hand hygiene will contribute to reducing 
the spread of both influenza and COVID-19.3
Our study has several limitations. Influenza vaccination 
status is self- reported in the Swiss Health Survey, and the 
reliability of the data unclear. For example, vaccination 
coverage could be lower if social desirability bias led to an 
overestimation of uptake. Conversely, incomplete recall 
of vaccinations could bias coverage downwards. Individ-
uals younger than 15 years are excluded from the survey, 
but coverage in this age group might be even lower than 
in the 15–19 years old. A strength of our analysis is the 
fact that the survey is a nationwide and representative, 
and repeated every 5 years using the same methodology. 
Also, the analyses were weighted and adjusted for a range 
of potential confounders, which did not substantially 
change the results.
In conclusion, we need to increase influenza vaccina-
tion uptake, particularly in the elderly and chronically 
ill, who are also the risk groups most heavily affected by 
COVID-19. These efforts should include classic informa-
tion campaigns, but novel approaches using social media 
should also be considered.33 34 Recommendations by 
healthcare professionals are essential to improve influ-
enza vaccination coverage, such as client reminder/recall 
and standing orders.35 The preparation of influenza 
season 2020/2021 must start now to address the double 
burden of COVID-19 and seasonal influenza.
Patient and public involvement
The Swiss Health Survey is a nationwide, representative 
survey that is repeated every 5 years using the same meth-
odology. The survey is conducted by the SFSO on behalf of 
the Swiss Government. The content of the survey is based 
on a holistic and dynamic health framework and contains 
questions on essential topics for the public and politics. 
The wording of the questions is regularly harmonised 
with the statistical offices of other countries in Europe.
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